Date: August 29, 2023 To: First Light Acquisition Group, Inc., a Delaware corporation (“FLAG”) and Calidi Biotherapeutics, Inc., a Nevada corporation (“Target”). Address: 11110 Sunset Hills Road #2278, Reston, VA, 20190 From: Funicular Funds, LP (as...Otc Equity Prepaid Forward Transaction • August 31st, 2023 • First Light Acquisition Group, Inc. • Biological products, (no disgnostic substances)
This Confirmation, together with the Pricing Date Notices, evidences a complete binding agreement between Seller, FLAG and Target as to the subject matter and terms of the Transaction to which this Confirmation relates and shall supersede all prior or contemporaneous written or oral communications with respect thereto.
Date: August 29, 2023 To: First Light Acquisition Group, Inc., a Delaware corporation (“FLAG”) and Calidi Biotherapeutics, Inc., a Nevada corporation (“Target”). Address: 11110 Sunset Hills Road #2278, Reston, VA, 20190 From: Great Point Capital LLC...Otc Equity Prepaid Forward Transaction • August 31st, 2023 • First Light Acquisition Group, Inc. • Biological products, (no disgnostic substances)
This Confirmation, together with the Pricing Date Notices, evidences a complete binding agreement between Seller, FLAG and Target as to the subject matter and terms of the Transaction to which this Confirmation relates and shall supersede all prior or contemporaneous written or oral communications with respect thereto.
Date: August 29, 2023 To: First Light Acquisition Group, Inc., a Delaware corporation (“FLAG”) and Calidi Biotherapeutics, Inc., a Nevada corporation (“Target”). Address: 11110 Sunset Hills Road #2278, Reston, VA, 20190 From: Marybeth Wootton (as...Otc Equity Prepaid Forward Transaction • August 31st, 2023 • First Light Acquisition Group, Inc. • Biological products, (no disgnostic substances)
This Confirmation, together with the Pricing Date Notices, evidences a complete binding agreement between Seller, FLAG and Target as to the subject matter and terms of the Transaction to which this Confirmation relates and shall supersede all prior or contemporaneous written or oral communications with respect thereto.